Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection

Journal of Medical Virology

Volumn 84, Issue 9, 2012, Pages 1360-1368

  Sueki, Ryota ^a   Maekawa, Shinya ^a   Miura, Mika ^a   Kadokura, Makoto ^a   Komase, Kazuki ^a   Shindo, Hiroko ^a   Kanayama, Asuka ^a   Ohmori, Takako ^a   Shindo, Kuniaki ^a   Amemiya, Fumitake ^a   Nakayama, Yasuhiro ^a   Uetake, Tomoyoshi ^a   Inoue, Taisuke ^a   Sakamoto, Minoru ^a   Enomoto, Nobuyuki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

HBV; Lamivudine resistance; ORF sequence analysis; Pre S substitution

Indexed keywords

AMINO ACID; LAMIVUDINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN READING FRAME; SEQUENCE ANALYSIS; VIRUS GENOME;

ADULT; AGED; ALANINE TRANSAMINASE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; GENES, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; OPEN READING FRAMES; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; STATISTICS, NONPARAMETRIC;

HEPATITIS B VIRUS;

EID: 84864132203     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23314     Document Type: Article

References (35)

1. Andersson KL, Chung RT. 2009. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 49: S166-S173.
2. Bauer T, Weinberger K, Jilg W. 2002. Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals. Hepatology 35: 455-465.
3. Carey I, Harrison PM. 2009. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 18: 1655-1666.
4. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. 2004. Occult hepatitis B virus infection in chronic liver disease: Full-length genome and analysis of mutant surface promoter. Gastroenterology 127: 1356-1371.
5. Chen CH, Lee CM, Lu SN, Changchien CS, Wang JC, Wang JH, Hung CH, Hu TH. 2006a. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol 44: 76-82.
6. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. 2006b. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73.
7. Chen EQ, Wang LC, Lei J, Xu L, Tang H. 2009. Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J 6: 163.
8. Cooper A, Paran N, Shaul Y. 2003. The earliest steps in hepatitis B virus infection. Biochim Biophys Acta 1614: 89-96.
9. De Meyer S, Gong ZJ, Suwandhi W, van Pelt J, Soumillion A, Yap SH. 1997. Organ and species specificity of hepatitis B virus (HBV) infection: A review of literature with a special reference to preferential attachment of HBV to human hepatocytes. J Viral Hepat 4: 145-153.
10. Fang ZL, Sabin CA, Dong BQ, Wei SC, Chen QY, Fang KX, Yang JY, Huang J, Wang XY, Harrison TJ. 2008. Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: A matched nested case-control study. J Gen Virol 89: 2882-2890.
11. Gao ZY, Li T, Wang J, Du JM, Li YJ, Li J, Lu FM, Zhuang H. 2007. Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma. J Gastroenterol 42: 761-768.
12. Ghany MG, Doo EC. 2009. Antiviral resistance and hepatitis B therapy. Hepatology 49: S174-S184.
13. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. 2006. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130: 678-686.
14. Kay A, Zoulim F. 2007. Hepatitis B virus genetic variability and evolution. Virus Res 127: 164-176.
15. Kobayashi M, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Sezaki H, Kawamura Y, Suzuki Y, Arase Y, Ikeda K, Mineta R, Iwasaki S, Watahiki S, Kumada H. 2009. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res 40: 125-134.
16. Leung N. 2000. Liver disease-significant improvement with lamivudine. J Med Virol 61: 380-385.
17. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33: 1527-1532.
18. Lian M, Zhou X, Chen B, Li C, Gu X, Luo M, Zheng X. 2008. Identification of the critical regions in hepatitis B virus preS required for its stability. J Pept Sci 14: 307-312.
19. Liang TJ. 2009. Hepatitis B: The virus and disease. Hepatology 49: S13-S21.
20. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119: 172-180.
21. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531.
22. Lim SG, Mohammed R, Yuen MF, Kao JH. 2009. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol 24: 1352-1357.
23. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24: 711-713.
24. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125: 1714-1722.
25. Ni Y, Sonnabend J, Seitz S, Urban S. 2010. The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly. J Virol 84: 3879-3888.
26. Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N. 2008. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus. J Infect Dis 198: 1150-1158.
27. Rizzetto M, Tassopoulos NC, Goldin RD, Esteban R, Santantonio T, Heathcote EJ, Lagget M, Taak NK, Woessner MA, Gardner SD. 2005. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol 42: 173-179.
28. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33: 751-757.
29. Sugauchi F, Mizokami M, Orito E, Ohno T, Kato H, Suzuki S, Kimura Y, Ueda R, Butterworth LA, Cooksley WG. 2001. A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: Complete genome sequence and phylogenetic relatedness. J Gen Virol 82: 883-892.
30. Sugauchi F, Ohno T, Orito E, Sakugawa H, Ichida T, Komatsu M, Kuramitsu T, Ueda R, Miyakawa Y, Mizokami M. 2003. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 70: 537-544.
31. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24: 714-717.
32. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. 2000. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31: 207-210.
33. Watanabe T, Sorensen EM, Naito A, Schott M, Kim S, Ahlquist P. 2007. Involvement of host cellular multivesicular body functions in hepatitis B virus budding. Proc Natl Acad Sci USA 104: 10205-10210.
34. Zhang KY, Imazeki F, Fukai K, Arai M, Kanda T, Mikata R, Yokosuka O. 2007. Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Sci 98: 1921-1929.
35. Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J. 2009. [Factors associated with response to lamivudine: Retrospective study of 233 patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi 17: 564-568.